Highlights vom EAU-Kongress 2019

Der jährliche Kongress der European Association of Urology (EAU) verbindet Wissenschaft und Praxis und bietet damit eine breite Plattform zur Weiterbildung. In den Sitzungen zu den wissenschaftlichen Fortschritten urologisch-onkologischer Erkrankungen wurden auch Hinweise diskutiert, die Möglichkeiten zu Optimierungen im klinischen Alltag geben.

• Literatur

• 1 Merseburger A. et al Primary results from SAUL, a prospective multinational single-arm study of atezolizumab for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract. EAU 2019 Abstract 5 BN
• 2 Ulibarri JI. et al CONUT: A tool for controlling nutrition status. First validation in a hospital population. Nutr Hosp 2005; 20: 38-45
• 3 Suzuki H. et al Prognostic significance of controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients. EAU 2019 Abstract 482
• 4 Ishihara H. et al Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. Urol Oncol 2017; 35 (539) e9-e16
• 5 Mazzone E. et al Identifying the optimal definition for early biochemical recurrence after radical prostatectomy: A risk-stratified approach to optimize postoperative follow-up and the use of timely salvage therapies. EAU 2019 Abstract 645
• 6 Towe M. et al Testosterone replacement therapy prevents disease progression in men undergoing radical prostatectomy. EAU 2019 Abstract 646
• 7 Bradshaw A. et al Does presence of bone metastases protend worsened prognosis in metastatic renal cell carcinoma? Analysis of the RMARCC (REgistry of MetAstatic RCC) database. EAU 2019 Abstract 875
• 8 Rodger F. et al Systematic review of the role of pancreatic metastatectomy in metastatic renal cell carcinoma (mRCC). EAU 2019 Abstract 877